Trial seekers use specific keywords in searches; FDA proposes conditions for PRO instruments;

> People searching for health information related to clinical research studies tend to use longer and more specific keywords in their Internet searches. Study

> Draft guidance from the FDA instructs that patient-reported outcome instruments can be used as the basis of product approval and labeling claims if: the measure is deemed to be a well-defined and reliable  assessment of the study objectives, the findings are supported by appropriately designed investigations, AND the instrument measures the concept represented by the claim [italics and capitalizations are FDA's]. Draft guidance

> California is asking hospitals to report any serious adverse events from the last several years or swear that none have occurred. Article

> SciQuest is growing and has expanded and extended the lease on its Cary, NC, headquarters. Article

> Business consultancy Huron has acquired Click Commerce and now offers software and services for managing basic research and clinical trials. Huron release

> Attendees at the ClearTrial annual user group meeting in Cambridge, MA, got a sneak preview of ClearTrial v4, the next major release. ClearTrial release

> Cato Research will implement BioClinica's clinical trial management system platform. Cato release

> The SEC has charged a clinical trial investigator with unlawfully tipping a hedge fund portfolio manager about problems with drug candidate. Article

> The National Quality Forum has endorsed a framework for the public reporting of patient safety events. NQF release

> Rensselaer Polytechnic has opened the Center for Modeling, Simulation, and Imaging in Medicine. RPI release

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.